reslizumab

01/01/2022 - "Treatment with reslizumab achieved complete asthma control in 40% of the 208 included SEUA patients and led to a significant reduction in exacerbations (from 3.0; IQR: 2.0-4.0 at V0 to 0.0; IQR: 0.0-0.0 at V2), maintenance OCS use (from 54.8% (95% CI: 48.0-61.6 at T0 to 18.5% (95% CI: 12.5-24.5 at T2) and a meaningful improvement in symptoms in the entire treated population: ACT increased from 12.8 ± 4.5 at V0 to 20.0 ± 5.1 at V2 (p < 0.001). "
05/01/2015 - "In both studies, patients receiving reslizumab had a significant reduction in the frequency of asthma exacerbations (study 1: rate ratio [RR] 0·50 [95% CI 0·37-0·67]; study 2: 0·41 [0·28-0·59]; both p<0·0001) compared with those receiving placebo. "
01/01/2021 - "Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU."
11/01/2020 - "Reslizumab reduced CAE frequency and improved lung function, asthma control, and QoL versus placebo in patients with severe eosinophilic asthma with a high CAE rate before treatment."
09/01/2019 - "The main objective was to determine whether treatment with reslizumab significantly improved asthma symptoms assessed by the Asthma Control Test (ACT) at week 24. "

04/01/2015 - "Rebound eosinophilia after cessation of reslizumab and attenuation of the treatment response with repeated dosing had been reported. "
12/01/2004 - "The rebound eosinophilia after SCH55700 treatment is a result of a serum factor that enhances eosinophil survival. "
04/15/2004 - "Reinstitution of treatment with monthly SCH55700 led to decreased eosinophilia and symptomatic improvement, albeit to a lesser degree than that seen after the initial dose. "
09/01/1999 - "In allergic rabbits, Sch 55700 blocks cutaneous eosinophilia. "
01/01/2017 - "Two phase III studies have demonstrated that reslizumab administration in adult patients with severe asthma and eosinophilia (≥400 cells/μL) improved lung function, asthma control, and symptoms. "

11/01/2019 - "Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab."
04/15/2004 - "Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome."
04/11/2022 - "This is the first report describing the effective use of reslizumab in a Korean adolescent patient for the management of lymphocytic-variant hypereosinophilic syndrome (L-HES). "
04/15/2004 - "Four patients with hypereosinophilic syndrome (HES) refractory to or intolerant of treatment with conventional therapy were treated with a single 1 mg/kg dose of SCH55700. "
01/01/2018 - "Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab."

10/01/2018 - "Efficacy of Reslizumab for Eosinophilic Esophagitis."
06/01/2018 - "Safety and Efficacy of Reslizumab for Children and Adolescents With Eosinophilic Esophagitis Treated for 9 Years."
02/01/2012 - "Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial."
02/01/2012 - "Reslizumab significantly reduced intraepithelial esophageal eosinophil counts in children and adolescents with eosinophilic esophagitis. "
07/01/2010 - "This article considers the current status of the clinical development of reslizumab for pediatric eosinophilic esophagitis."

01/01/2021 - "Treatment with reslizumab in patients with eosinophilic asthma and concomitant CRS with polyps and chronic non-allergic rhinitis (NARES) leads not only to improved control of asthma symptoms, but also to a significant regression of nasal symptoms. "
01/01/2021 - "To evaluate the therapeutic potential of reslizumab-humanized anti-IL-5 monoclonal antibody for the treatment of CRS with polyps in patients with severe asthma. "
11/01/2006 - "We evaluated the safety and pharmacokinetics of reslizumab, and biologic activity was assessed by means of endoscopic evaluation of polyp size, symptoms, peripheral eosinophil counts, peripheral and local IL-5 levels, eotaxin levels, and eosinophil cationic protein levels. "
10/01/2021 - "Phase 3 trials for omalizumab (POLYP 1 and 2) and mepolizumab (SYNAPSE study) and post hoc analyses of phase 3 asthma studies for reslizumab and benralizumab have also demonstrated positive results for the use of biologics for patients with CRSwNP. "